GPR119 agonist AS1269574 activates TRPA1 cation channels to stimulate GLP-1 secretion

Molecular Endocrinology

Volumn 30, Issue 6, 2016, Pages 614-629

  Chepurny, Oleg G ^a   Holz, George G ^a   Roe, Michael W ^a,b   Leech, Colin A ^a  

^a STATE UNIVERSITY OF NEW YORK   (United States)

^b State University of New York Upstate Medical University: College of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; AS 1269574; CALCIUM; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 119 AGONIST; GLUCAGON LIKE PEPTIDE 1; PROGLUCAGON; TRANSIENT RECEPTOR POTENTIAL CHANNEL A1; UNCLASSIFIED DRUG; 2,3,4-TRI-O-ACETYLARABINOPYRANOSYL ISOTHIOCYANATE; 2-(2-(4-BROMOPHENYL)-6-METHYLPYRIMIDIN-4-YL)AMINOETHANOL; CARVACROL; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; ETHANOLAMINE DERIVATIVE; GLUCAGON; ISOTHIOCYANIC ACID DERIVATIVE; LUCIFERASE; MUTANT PROTEIN; PYRIMIDINE DERIVATIVE; RECOMBINANT PROTEIN; TERPENE;

ARTICLE; CALCIUM TRANSPORT; CELL FUNCTION; CONTROLLED STUDY; DESENSITIZATION; ENDOPLASMIC RETICULUM; GENE EXPRESSION; GENETIC TRANSFECTION; L CELL LINE; MEMBRANE CURRENT; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN SECRETION; PROTEIN SYNTHESIS; REPORTER GENE; WILD TYPE; ANIMAL; ANTAGONISTS AND INHIBITORS; CHANNEL GATING; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HEK293 CELL LINE; HUMAN; METABOLISM; RAT; SECRETION (PROCESS);

ANIMALS; CALCIUM; CYCLIC AMP; CYCLIC AMP-DEPENDENT PROTEIN KINASES; ENDOPLASMIC RETICULUM; ETHANOLAMINES; GENE EXPRESSION REGULATION; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HEK293 CELLS; HUMANS; ION CHANNEL GATING; ISOTHIOCYANATES; LUCIFERASES; MONOTERPENES; MUTANT PROTEINS; PROGLUCAGON; PYRIMIDINES; RATS; RECEPTORS, G-PROTEIN-COUPLED; RECOMBINANT PROTEINS; TRANSFECTION; TRPA1 CATION CHANNEL;

EID: 84971646938     PISSN: 08888809     EISSN: 19449917     Source Type: Journal    
DOI: 10.1210/me.2015-1306     Document Type: Article

References (69)

1. Gamble JM, Clarke A, Myers KJ, et al. Incretin-based medications for type 2 diabetes: an overview of reviews. Diabetes Obes Metab. 2015;17:649–658.
2. Trujillo JM, Nuffer W, Ellis SL. GLP-1 receptor agonists: a review of head-to-head clinical studies. Ther Adv Endocrinol Metab. 2015; 6:19–28.
3. Scheen AJ. Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes. Expert Opin Drug Saf. 2015;14:505–524.
4. Semple G, Fioravanti B, Pereira G, et al. Discovery of the first potent and orally efficacious agonist of the orphan G-protein coupled receptor 119. J Med Chem. 2008;51:5172–5175.
5. Chu ZL, Carroll C, Alfonso J, et al. A role for intestinal endocrine cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucagon-like peptide-1 and glucose-dependent insulinotropic peptide release. Endocrinology. 2008;149:2038–2047.
6. Overton HA, Fyfe MC, Reynet C. GPR119, a novel G proteincoupled receptor target for the treatment of type 2 diabetes and obesity. Br J Pharmacol. 2008;153(suppl 1):S76–S81.
7. Chepurny OG, Bertinetti D, Diskar M, et al. Stimulation of proglucagon gene expression by human GPR119 in enteroendocrine L-cell line GLUTag. Mol Endocrinol. 2013;27:1267–1282.
8. Li Y, Kokrashvili Z, Mosinger B, Margolskee RF. Gustducin couples fatty acid receptors to GLP-1 release in colon. Am J Physiol Endocrinol Metab. 2013;304:E651–E660.
9. Ritter K, Buning C, Halland N, Poverlein C, Schwink L. G proteincoupled receptor 119 (GPR119) agonists for the treatment of diabetes: recent progress and prevailing challenges. J Med Chem. In press.
10. Negoro K, Yonetoku Y, Misawa-Mukai H, et al. Discovery and biological evaluation of novel 4-amino-2-phenylpyrimidine derivatives as potent and orally active GPR119 agonists. Bioorg Med Chem. 2012;20:5235–5246.
11. Negoro K, Yonetoku Y, Moritomo A, et al. Synthesis and structureactivity relationship of fused-pyrimidine derivatives as a series of novel GPR119 agonists. Bioorg Med Chem. 2012;20:6442–6451.
12. Yoshida S, Ohishi T, Matsui T, Shibasaki M. Identification of a novel GPR119 agonist, AS1269574, with in vitro and in vivo glucose- stimulated insulin secretion. Biochem Biophys Res Commun. 2010;400:437–441.
13. Yoshida S, Ohishi T, Matsui T, et al. Novel GPR119 agonist AS1535907 contributes to first-phase insulin secretion in rat perfused pancreas and diabetic db/db mice. Biochem Biophys Res Commun. 2010;402:280–285.
14. Yoshida S, Ohishi T, Matsui T, et al. The role of small molecule GPR119 agonist, AS1535907, in glucose-stimulated insulin secretion and pancreatic β-cell function. Diabetes Obes Metab. 2011; 13:34–41.
15. Yoshida S, Tanaka H, Oshima H, et al. AS1907417, a novel GPR119 agonist, as an insulinotropic and β-cell preservative agent for the treatment of type 2 diabetes. Biochem Biophys Res Commun. 2010;400:745–751.
16. Drucker DJ, Jin T, Asa SL, Young TA, Brubaker PL. Activation of proglucagon gene transcription by protein kinase A in a novel mouse enteroendocrine cell line. Mol Endocrinol. 1994;8:1646–1655.
17. Abello J, Ye F, Bosshard A, Bernard C, Cuber JC, Chayvialle JA. Stimulation of glucagon-like peptide-1 secretion by muscarinic agonist in a murine intestinal endocrine cell line. Endocrinology. 1994;134:2011–2017.
18. Grant SG, Seidman I, Hanahan D, Bautch VL. Early invasiveness characterizes metastatic carcinoid tumors in transgenic mice. Cancer Res. 1991;51:4917–4923.
19. Rindi G, Grant SG, Yiangou Y, et al. Development of neuroendocrine tumors in the gastrointestinal tract of transgenic mice. Heterogeneity of hormone expression. Am J Pathol. 1990;136:1349–1363.
20. Jin T, Drucker DJ. Activation of proglucagon gene transcription through a novel promoter element by the caudal-related homeodomain protein cdx-2/3. Mol Cell Biol. 1996;16:19–28.
21. Engelstoft MS, Norn C, Hauge M, et al. Structural basis for constitutive activity and agonist-induced activation of the enteroendocrine fat sensor GPR119. Br J Pharmacol. 2014;171:5774–5789.
22. Nilius B, Appendino G, Owsianik G. The transient receptor potential channel TRPA1: from gene to pathophysiology. Pflugers Arch. 2012;464:425–458.
23. Emery EC, Diakogiannaki E, Gentry C, et al. Stimulation of GLP-1 secretion downstream of the ligand-gated ion channel TRPA1. Diabetes. 2015;64:1202–1210.
24. 2+ and cAMP signaling in the insulin-secreting MIN6 β-cell line. J Biol Chem. 2005;280:31294–31302.
25. 2+ and cAMP in single cells. Sci STKE. 2006;2006(353):p16.
26. 2+ analyzed with an improved genetically encoded fluorescent sensor. Proc Natl Acad Sci USA. 2004; 101(50):17404–17409.
27. Allen MD, Zhang J. Subcellular dynamics of protein kinase A activity visualized by FRET-based reporters. Biochem Biophys Res Commun. 2006;348:716–721.
28. Holz GG, Leech CA, Roe MW, Chepurny OG. High-throughput FRET assays for fast time-resolved detection of cyclic AMP in pancreatic β cells. In: Cheng X, ed. Cyclic Nucleotide Signaling. Boca Raton, FL: CRC Press; 2014:35–60.
29. Schwede F, Chepurny OG, Kaufholz M, et al. Rp-cAMPS prodrugs reveal the cAMP dependence of first-phase glucose-stimulated insulin secretion. Mol Endocrinol. 2015;29:988–1005.
30. Leech CA, HolzGG4th. Application of patch clamp methods to the study of calcium currents and calcium channels. Methods Cell Biol. 1994;40:135–151.
31. Chepurny OG, Holz GG. A novel cyclic adenosine monophosphate responsive luciferase reporter incorporating a nonpalindromic cyclic adenosine monophosphate response element provides optimal performance for use in G protein coupled receptor drug discovery efforts. J Biomol Screen. 2007;12:740–746.
32. Tolhurst G, Reimann F, Gribble FM. Nutritional regulation of glucagon-like peptide-1 secretion. J Physiol. 2009;587:27–32.
33. 2+ influx. J Endocrinol. 2009;201:361–367.
34. Mangel AW, Scott L, Liddle RA. Depolarization-stimulated cholecystokinin secretion is mediated by L-type calcium channels in STC-1 cells. Am J Physiol. 1996;270:G287–G290.
35. Mangel AW, Snow ND, Misukonis MA, et al. Calcium-dependent regulation of cholecystokinin secretion and potassium currents in STC-1 cells. Am J Physiol. 1993;264:G1031–G1036.
36. Catterall WA. Voltage-gated calcium channels. Cold Spring Harb Perspect Biol. 2011;3(8):a003947.
37. Sieman, D. Nonselective cation channels. In: Siemen D, Hescheler J, eds. Nonselective Cation Channels: Pharmacology, Physiology, and Biophysics. Vol 66 of Experientia Supplementum. Basel, Switzerland: Birkhäuser; 1993:3–25.
38. Miura S, Takahashi K, Imagawa T, Uchida K, Saito S, Tominaga M, Ohta T. Involvement of TRPA1 activation in acute pain induced by cadmium in mice. Mol Pain. 2013;9:7.
39. Chen J, Joshi SK, DiDomenico S, et al. Selective blockade of TRPA1 channel attenuates pathological pain without altering noxious cold sensation or body temperature regulation. Pain. 2011;152(5): 1165–1172.
40. Doerner JF, Gisselmann G, Hatt H, Wetzel CH. Transient receptor potential channel A1 is directly gated by calcium ions. J Biol Chem. 2007;282(18):13180–13189.
41. 2+. Nat Neurosci. 2007;10(3):277–279.
42. Purhonen AK, Louhivuori LM, Kiehne K, Kerman KE, Herzig KH. TRPA1 channel activation induces cholecystokinin release via extracellular calcium. FEBS Lett. 2008;582:229–232.
43. Motter AL, Ahern GP. TRPA1 is a polyunsaturated fatty acid sensor in mammals. PLoS One. 2012;7(6):e38439.
44. McClenaghan C, Zeng F, Verkuyl JM. TRPA1 agonist activity of probenecid desensitizes channel responses: consequences for screening. Assay Drug Dev Technol. 2012;10(6):533–541.
45. Kurogi M, Miyashita M, Emoto Y, Kubo Y, Saitoh O. Green tea polyphenol epigallocatechin gallate activates TRPA1 in an intestinal enteroendocrine cell line, STC-1. Chem Senses. 2012;37(2): 167–177.
46. Kim HY, Park M, Kim K, Lee YM, Rhyu MR. Hesperetin stimulates cholecystokinin secretion in enteroendocrine STC-1 cells. Biomol Ther (Seoul). 2013;21(2):121–125.
47. Nakajima S, Hira T, Yahagi A, et al. Unsaturated aldehydes induce CCK secretion via TRPA1 in STC-1 cells. Mol Nutr Food Res. 2014;58(5):1042–1051.
48. Bandell M, Story GM, Hwang SW, et al. Noxious cold ion channel TRPA1 is activated by pungent compounds and bradykinin. Neuron. 2004;41(6):849–857.
49. Xu H, Delling M, Jun JC, Clapham DE. Oregano, thyme and clovederived flavors and skin sensitizers activate specific TRP channels. Nat Neurosci. 2006;9(5):628–635.
50. McNamara CR, Mandel-Brehm J, Bautista DM, et al. TRPA1 mediates formalin-induced pain. Proc Natl Acad Sci USA. 2007; 104(33):13525–13530.
51. Petrus M, Peier AM, Bandell M, et al. A role of TRPA1 in mechanical hyperalgesia is revealed by pharmacological inhibition. Mol Pain. 2007;3:40.
52. Wang YY, Chang RB, Waters HN, McKemy DD, Liman ER. The nociceptor ion channel TRPA1 is potentiated and inactivated by permeating calcium ions. J Biol Chem. 2008;283(47):32691–32703.
53. Atwood BK, Lopez J, Wager-Miller J, Mackie K, Straiker A. Expression of G protein-coupled receptors and related proteins in HEK293, AtT20, BV2, and N18 cell lines as revealed by microarray analysis. BMC Genomics. 2011;12:14.
54. Zhang SY, Li J, Xie X. Discovery and characterization of novel small molecule agonists of G protein-coupled receptor 119. Acta Pharmacol Sin. 2014;35(4):540–548.
55. Hinman A, Chuang HH, Bautista DM, Julius D. TRP channel activation by reversible covalent modification. Proc Natl Acad Sci USA. 2006;103:19564–19568.
56. Macpherson LJ, Dubin AE, Evans MJ, et al. Noxious compounds activate TRPA1 ion channels through covalent modification of cysteines. Nature. 2007;445:541–545.
57. Wang YY, Chang RB, Allgood SD, Silver WL, Liman ER. A TRPA1-dependent mechanism for the pungent sensation of weak acids. J Gen Physiol. 2011;137:493–505.
58. +-glucose cotransporter 1. Proc Natl Acad Sci USA. 2007;104(38):15075–15080.
59. Cao DS, Zhong L, Hsieh TH, et al. Expression of transient receptor potential ankyrin 1 (TRPA1) and its role in insulin release from rat pancreatic β cells. PLoS One. 2012;7:e38005.
60. Moran BM, Abdel-Wahab YH, Flatt PR, McKillop AM. Activation of GPR119 by fatty acid agonists augments insulin release from clonal β-cells and isolated pancreatic islets and improves glucose tolerance in mice. Biol Chem. 2014;395:453–464.
61. Bautista DM, Jordt SE, Nikai T, et al. TRPA1 mediates the inflammatory actions of environmental irritants and proalgesic agents. Cell. 2006;124:1269–1282.
62. Mickle AD, Shepherd AJ, Mohapatra DP. Sensory TRP channels: the key transducers of nociception and pain. Prog Mol Biol Transl Sci. 2015;131:73–118.
63. Boesmans W, Owsianik G, Tack J, Voets T, Vanden Berghe P. TRP channels in neurogastroenterology: opportunities for therapeutic intervention. Br J Pharmacol. 2011;162:18–37.
64. Fernandes ES, Fernandes MA, Keeble JE. The functions of TRPA1 and TRPV1: moving away from sensory nerves. Br J Pharmacol. 2012;166:510–521.
65. Faerch K, Torekov SS, Vistisen D, et al. GLP-1 response to oral glucose is reduced in prediabetes, screen-detected type 2 diabetes, and obesity and influenced by sex: the ADDITION-PRO study. Diabetes. 2015;64:2513–2525.
66. Camacho S, Michlig S, de Senarclens-Bezencon C, et al. Anti-obesity and anti-hyperglycemic effects of cinnamaldehyde via altered ghrelin secretion and functional impact on food intake and gastric emptying. Sci Rep. 2015;5:7919.
67. Nozawa K, Kawabata-Shoda E, Doihara H, et al. TRPA1 regulates gastrointestinal motility through serotonin release from enterochromaffin cells. Proc Natl Acad Sci USA. 2009;106:3408–3413.
68. Holz GG, Chepurny OG. Glucagon-like peptide-1 synthetic analogs: new therapeutic agents for use in the treatment of diabetes mellitus. Curr Med Chem. 2003;10:2471–2483.
69. Nadkarni P, Chepurny OG, Holz GG. Regulation of glucose homeostasis by GLP-1. Prog Mol Biol Transl Sci. 2014;121:23–65.